Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Top Cited Papers
- 14 January 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (2), 117-128
- https://doi.org/10.1056/nejmoa2030183
Abstract
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.Keywords
Funding Information
- Sanofi
- Lexicon Pharmaceuticals
This publication has 51 references indexed in Scilit:
- Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trialsThe Lancet Diabetes & Endocrinology, 2015
- Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 TrialDiabetes Care, 2014
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized TrialCirculation, 2014
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusThe New England Journal of Medicine, 2013
- Clopidogrel with or without Omeprazole in Coronary Artery DiseaseThe New England Journal of Medicine, 2010
- Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With AtherothrombosisJAMA, 2010
- One-Year Cardiovascular Event Rates in Outpatients With AtherothrombosisJAMA, 2007
- International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With AtherothrombosisJAMA, 2006
- Standardized rates of recurrent outcomesStatistics in Medicine, 1994
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989